Siesky Brent, Harris Alon, Sines Daniel, Rechtman Ehud, Malinovsky Victor E, McCranor Lynne, Yung Chi-Wah, Zalish Miriam
Department of Ophthalmology, Indiana University School of Medicine, Indianapolis, IN 46202, USA.
J Ocul Pharmacol Ther. 2006 Oct;22(5):353-61. doi: 10.1089/jop.2006.22.353.
The aim of this study was to assess the effects of fixed combination of timolol and dorzolamide and latanoprost plus timolol on retinal, choroidal, and retrobulbar hemodynamics and visual function in primary open-angle glaucoma (OAG) subjects.
Sixteen (16) OAG patients (age, 63.5 +/- 10.8 years; 9 male) were evaluated in a randomized, crossover, double-blind study design after 4 weeks of treatment of latanoprost with timolol and fixed combination of timolol and dorzolamide. After randomization, 9 right eyes and 7 left eyes were included in the hemodynamic portion of the study. Measurements included: adverse events check, visual acuity, contrast sensitivity, blood pressure, heart rate, intraocular pressure (IOP), and fundus examination. Ocular blood flow was assessed using confocal scanning laser Doppler flowmetry, color Doppler imaging, and scanning laser ophthalmoscopy.
Both therapies were effective at lowering IOP, whereas there was no statistically significant difference between latanoprost plus timolol and the fixed combination of timolol and dorzolamide (13.9% and 12.2% reduction, respectively; P = 0.5533). Fixed combination of timolol and dorzolamide significantly increased central retinal artery end diastolic blood flow velocity (P = 0.0168) and lowered resistance to flow (P = 0.0279). Temporal posterior ciliary artery peak systolic and end diastolic velocities were significantly increased with the fixed combination of timolol and dorzolamide (P = 0.0125 and 0.0238, respectively). Latanoprost plus timolol had no significant effects on ocular blood flow during 4 weeks of treatment. There were no statistically significant differences in adverse events, blood pressure, heart rate, visual acuity, contrast sensitivity scanning laser ophthalmoscopy, or Heidelberg Retinal Flowmeter for any treatment period.
Fixed combination of timolol and dorzolamide therapy might increase blood flow in OAG patients while attaining a similar IOP reduction compared to latanoprost plus timolol. Visual function, however, was not different in this short-term comparison between the two treatments.
本研究旨在评估噻吗洛尔与多佐胺固定复方制剂以及拉坦前列素联合噻吗洛尔对原发性开角型青光眼(OAG)患者视网膜、脉络膜及球后血流动力学和视觉功能的影响。
16例OAG患者(年龄63.5±10.8岁;男性9例)在接受拉坦前列素与噻吗洛尔以及噻吗洛尔与多佐胺固定复方制剂治疗4周后,采用随机、交叉、双盲研究设计进行评估。随机分组后,研究的血流动力学部分纳入了9只右眼和7只左眼。测量指标包括:不良事件检查、视力、对比敏感度、血压、心率、眼压(IOP)和眼底检查。使用共焦扫描激光多普勒血流仪、彩色多普勒成像和扫描激光检眼镜评估眼血流。
两种治疗方法均能有效降低眼压,然而拉坦前列素联合噻吗洛尔与噻吗洛尔和多佐胺固定复方制剂之间无统计学显著差异(分别降低13.9%和12.2%;P = 0.5533)。噻吗洛尔和多佐胺固定复方制剂显著增加视网膜中央动脉舒张末期血流速度(P = 0.0168)并降低血流阻力(P = 0.0279)。噻吗洛尔和多佐胺固定复方制剂使颞侧睫状后动脉收缩期峰值和舒张末期速度显著增加(分别为P = 0.0125和0.0238)。拉坦前列素联合噻吗洛尔在治疗4周期间对眼血流无显著影响。在任何治疗期间,不良事件、血压心率视力、对比敏感度、扫描激光检眼镜或海德堡视网膜血流仪方面均无统计学显著差异。
噻吗洛尔和多佐胺固定复方制剂治疗可能会增加OAG患者的血流,同时与拉坦前列素联合噻吗洛尔相比,降低眼压的效果相似。然而,在这两种治疗方法的短期比较中,视觉功能并无差异。